Researcher
Sébastien Anguille
- Research Expertise:Cancer; hematological malignancies; acute myeloid leukemia; immunotherapy; dendritic cells; gene-modified T cells including chimeric antigen receptor (CAR) T cell; translational research; clinical studies
- Keywords:T CYTOTOXIC LYMPHOCYTE, DENDRITIC CELLS, CLINICAL TRIAL, CANCER VACCINES, CANCER IMMUNOTHERAPY, ELECTROPORATION, Medicine
- Disciplines:Hematology, Cancer therapy
- Research techniques:Cell culture; multiparameter flow cytometry; ELISA and ELISpot; cytotoxicity experiments; mRNA electroporation; GMP production of dendritic cell vaccines and CAR-T cells
- Users of research expertise:Academia; biotech companies; pharmaceutical companies
Affiliations
- Laboratory for Experimental Hematology (LEH) (Research group)
Responsible
From1 Oct 2020 → Today - Laboratory for Experimental Hematology (LEH) (Research group)
Member
From1 Jan 2019 → 30 Sep 2020 - Vaccine & Infectious Disease Institute (VAXINFECTIO) (Research group)
Member
From1 Oct 2018 → 31 Dec 2018 - Vaccine & Infectious Disease Institute (VAXINFECTIO) (Research group)
Member
From1 Oct 2008 → 31 Jul 2013
Projects
1 - 10 of 16
- Development of a novel chimeric antigen receptor (CAR)-T cell therapy for acute myeloid leukemia.From1 Oct 2023 → TodayFunding: BOF - doctoral mandates
- BCMA immunoPET to predict and monitor treatment response to CAR-based cellular therapies in multiple myeloma.From1 Jan 2023 → TodayFunding: FWO research project (including WEAVE projects)
- Learning the design language of CAR structural components using a high-throughput screening method.From1 Sep 2022 → 28 Feb 2023Funding: Foreign Nonprofit organisations and equivalents
- Targeting the NF-κB pathway with targeted protein degradation for the treatment of hematological malignancies.From1 Sep 2022 → TodayFunding: Baekeland
- Flow Cytometry and Cell Sorting Core Facility Uantwerpen (FACSUA)From1 Jan 2022 → TodayFunding: BOF - research organisations
- MulTplex project: Innovating on combinatorial genetically engineered adoptive Tcell therapies against hematological diseases.From1 Nov 2021 → 31 Oct 2022Funding: Nonprofit institution or equivalents
- Preclinical development of novel chimeric antigen receptor (CAR)-modified cell-based immunotherapy approaches for hematological malignancies.From1 Oct 2021 → TodayFunding: BOF - doctoral mandates
- Post-transplant infusion of CD19 CAR-armored donor lymphocytes in adult patients with B-cell hematological malignancies: a phase I/IIa study.From1 Oct 2021 → TodayFunding: Nonprofit institution or equivalents
- ANCHOR project - Antigenspecific non signaling CARs as hemato-oncological remedy.From22 Jun 2021 → 22 Jun 2022Funding: Foundations, funds and other with scientific goal
- Identification and validation of T cell receptor (TCR) pairs for TCR-T cell therapy for AML and NHL (HEME TCR).From1 Jun 2021 → TodayFunding: VLAIO - research project companies
Publications
21 - 30 of 81
- Absence of BCL-2 expression identifies a subgroup of AML with distinct phenotypic, molecular, and clinical characteristics(2020)
Authors: Inke De haes, Marie Le Mercier, Pauline Puylaert, Katrien Vermeulen, Mark Kockx, Kathleen Deiteren, Marie-Berthe Maes, Zwi Berneman, Sébastien Anguille
- Chimeric antigen receptor-T-cell therapy for B-cell hematological malignancies(2020)
Authors: Gils Roex, Tom Feys, Yves Beguin, Tessa Kerre, Xavier Poiré, Philippe Lewalle, Peter Vandenberghe, Dominique Bron, Sébastien Anguille
Pages: 1 - 15 - Het Wilms'tumor 1 (WT1) eiwit als target voor gepersonaliseerde immuuntherapie bij kanker(2020)
Authors: Jolien Van den Bossche, Sébastien Anguille, Yannick Willemen, Ann Van de Velde, Wai Ping Lee, Eva Lion, Evelien Smits, Marc Peeters, Zwi Berneman
Pages: 25 - 26 - Rapid assessment of functional avidity of tumor-specific T cell receptors using an antigen-presenting tumor cell line electroporated with full-length tumor antigen mRNA(2020)
Authors: Diana Campillo Davó, Maarten Versteven, Gils Roex, Hans De Reu, Sébastien Anguille, Zwi Berneman, Vigor Van Tendeloo, Eva Lion
Pages: 1 - 15 - Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma(2020)
Authors: Gils Roex, Marijke Timmers, Diana Campillo Davó, Donovan Flumens, Wilfried Schroyens, Yiwei Chu, Zwi Berneman, Eva Lion, Feifei Luo, Sébastien Anguille
- Cellulaire immuuntherapie bij kanker(2019)
Authors: Ann Van de Velde, Sébastien Anguille, Wai Ping Lee, Jolien Van den Bossche, Evelien Smits, Zwi Berneman
Pages: 244 - 247 - Chimeric antigen receptor-modified T cell therapy in multiple myeloma(2019)
Authors: Marijke Timmers, Gils Roex, Yuedi Wang, Diana Campillo Davó, Vigor Van Tendeloo, Yiwei Chu, Zwi Berneman, Feifei Luo, Heleen Van Acker, Sébastien Anguille
- Dendritic cell-based immunotherapy of acute myeloid leukemia(2019)
Authors: Heleen Van Acker, Maarten Versteven, Felix S. Lichtenegger, Gils Roex, Diana Campillo Davó, Eva Lion, Marion Subklewe, Vigor Van Tendeloo, Zwi Berneman, Sébastien Anguille
- Chimeric antigen receptor T-cells(2019)
Authors: T. Feys, Gils Roex, Y. Beguin, T. Kerre, X. Poiré, P. Lewalle, P. Vandenberghe, D. Bron, Sébastien Anguille
Pages: 301 - 310 - CD56 homodimerization and participation in anti-tumor immune effector cell functioning(2019)
Authors: Heleen Van Acker, Zoë Van Acker, Maarten Versteven, Peter Ponsaerts, Daniela Pende, Zwi Berneman, Sébastien Anguille, Vigor Van Tendeloo, Evelien Smits